首页 > 最新文献

American journal of translational research最新文献

英文 中文
Analysis of risk factors for PCI no-reflow in coronary heart disease and construction of related prediction models. 冠心病 PCI 无回流风险因素分析及相关预测模型的构建。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.62347/ECNI6080
Liang Zhang, Jun Lin, Lintao Luo, Bin Liu, Xiaojuan Zeng

Objective: To analyze the risk factors of percutaneous coronary intervention (PCI) no-reflow in patients with coronary heart disease (CHD) and construct a predictive nomogram model.

Methods: This retrospective study included 260 patients with CHD who underwent PCI in the Third Affiliated Hospital of Chongqing Medical University from January 2022 to December 2023. The subjects were divided into a PCI no-reflow group (n = 86) and normal reflow group (n = 174) based on thrombolysis in myocardial infarction (TIMI) blood flow grading. General data, PCI related data and laboratory indexes of patients were collected. Logistic regression was used to analyze the risk factors of no-reflow after PCI in CHD patients. Based on the significant variables from regression analysis, a nomogram prediction model was constructed by using R language. The accuracy of the model was evaluated by receiver operating characteristic (ROC) curve and calibration curve, and the decision curve was drawn to clarify the clinical utility of the model. Model performance metrics included area under the curve (AUC), accuracy, sensitivity and specificity.

Results: Multivariate logistic regression analysis showed that hypertension, cystatin C (Cys-C), hypersensitive c-reactive protein (hs-CRP) and platelet-to-lymphocyte ratio (PLR) were risk factors for no-reflow after PCI in CHD patients (OR > 1, P < 0.001), while ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS-13) and lymphocyte (LYM) were protective factors (OR < 1, P < 0.001). The nomogram prediction model based on the above risk factors showed good predictive value. The AUC of the nomogram prediction model in the training set was 0.967 (95% CI: 0.946-0.989), with a specificity of 0.923 and a sensitivity of 0.908. In the validation set, the AUC was 0.894 (95% CI: 0.817-0.971), with a specificity of 0.807 and a sensitivity of 0.857. The calibration curve indicated good agreement between the predicted and actual probabilities, and the decision curve showed clinical benefit across a range of threshold probabilities in both the training and validation sets (0.0-0.99).

Conclusion: The risk factors affecting the occurrence of no-reflow after PCI in patients with CHD include hypertension, serum Cys-C, hs-CRP, PLR, ADAMTS-13 and LYM levels. The nomogram risk prediction model based on the above factors is valuable for identifying patients with high risk of no-reflow after PCI.

目的分析冠心病(CHD)患者经皮冠状动脉介入治疗(PCI)无回流的风险因素,并构建预测性提名图模型:该回顾性研究纳入了2022年1月至2023年12月在重庆医科大学附属第三医院接受PCI治疗的260例冠心病患者。根据心肌梗死溶栓治疗(TIMI)血流分级将受试者分为 PCI 无回流组(n = 86)和正常回流组(n = 174)。收集了患者的一般数据、PCI 相关数据和实验室指标。采用逻辑回归分析冠心病患者PCI术后无血流回流的风险因素。根据回归分析中的重要变量,使用 R 语言构建了一个提名图预测模型。通过接收者操作特征曲线(ROC)和校准曲线评估了模型的准确性,并绘制了决策曲线以明确模型的临床实用性。模型的性能指标包括曲线下面积(AUC)、准确性、灵敏度和特异性:多变量逻辑回归分析表明,高血压、胱抑素C(Cys-C)、超敏c反应蛋白(hs-CRP)和血小板与淋巴细胞比值(PLR)是导致CHD患者PCI术后无再流的危险因素(OR>1,P<0.001),而ADAM金属肽酶与凝血酶原1型基序13(ADAMTS-13)和淋巴细胞(LYM)是保护因素(OR<1,P<0.001)。基于上述风险因素的提名图预测模型显示出良好的预测价值。在训练集中,提名图预测模型的AUC为0.967(95% CI:0.946-0.989),特异性为0.923,灵敏度为0.908。在验证集中,AUC 为 0.894(95% CI:0.817-0.971),特异性为 0.807,灵敏度为 0.857。校准曲线显示预测概率与实际概率之间的一致性很好,决策曲线显示在训练集和验证集的阈值概率范围内(0.0-0.99)都有临床益处:结论:影响冠心病患者PCI术后无复流的风险因素包括高血压、血清Cys-C、hs-CRP、PLR、ADAMTS-13和LYM水平。基于上述因素的提名图风险预测模型对识别 PCI 后无复流高风险患者很有价值。
{"title":"Analysis of risk factors for PCI no-reflow in coronary heart disease and construction of related prediction models.","authors":"Liang Zhang, Jun Lin, Lintao Luo, Bin Liu, Xiaojuan Zeng","doi":"10.62347/ECNI6080","DOIUrl":"https://doi.org/10.62347/ECNI6080","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the risk factors of percutaneous coronary intervention (PCI) no-reflow in patients with coronary heart disease (CHD) and construct a predictive nomogram model.</p><p><strong>Methods: </strong>This retrospective study included 260 patients with CHD who underwent PCI in the Third Affiliated Hospital of Chongqing Medical University from January 2022 to December 2023. The subjects were divided into a PCI no-reflow group (n = 86) and normal reflow group (n = 174) based on thrombolysis in myocardial infarction (TIMI) blood flow grading. General data, PCI related data and laboratory indexes of patients were collected. Logistic regression was used to analyze the risk factors of no-reflow after PCI in CHD patients. Based on the significant variables from regression analysis, a nomogram prediction model was constructed by using R language. The accuracy of the model was evaluated by receiver operating characteristic (ROC) curve and calibration curve, and the decision curve was drawn to clarify the clinical utility of the model. Model performance metrics included area under the curve (AUC), accuracy, sensitivity and specificity.</p><p><strong>Results: </strong>Multivariate logistic regression analysis showed that hypertension, cystatin C (Cys-C), hypersensitive c-reactive protein (hs-CRP) and platelet-to-lymphocyte ratio (PLR) were risk factors for no-reflow after PCI in CHD patients (OR > 1, P < 0.001), while ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS-13) and lymphocyte (LYM) were protective factors (OR < 1, P < 0.001). The nomogram prediction model based on the above risk factors showed good predictive value. The AUC of the nomogram prediction model in the training set was 0.967 (95% CI: 0.946-0.989), with a specificity of 0.923 and a sensitivity of 0.908. In the validation set, the AUC was 0.894 (95% CI: 0.817-0.971), with a specificity of 0.807 and a sensitivity of 0.857. The calibration curve indicated good agreement between the predicted and actual probabilities, and the decision curve showed clinical benefit across a range of threshold probabilities in both the training and validation sets (0.0-0.99).</p><p><strong>Conclusion: </strong>The risk factors affecting the occurrence of no-reflow after PCI in patients with CHD include hypertension, serum Cys-C, hs-CRP, PLR, ADAMTS-13 and LYM levels. The nomogram risk prediction model based on the above factors is valuable for identifying patients with high risk of no-reflow after PCI.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of Th17/Treg associated transcription factors with clinicopathological features of colorectal cancer and their prognostic significance. Th17/Treg相关转录因子与结直肠癌临床病理特征的相关性及其预后意义。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.62347/IOAM8718
Jianqiang Pan, Zhengrong Su, Zhihong Liu, Xingwei Zhong

Objective: To analyze the correlation of Th17/Treg associated transcription factors (TFs) with clinicopathological features of colorectal cancer (CRC) and their prognostic significance.

Methods: This research enrolled 56 CRC patients (experimental group, EG) and 50 healthy controls (control group, CG), who presented to Deqing People's Hospital between June 2017 and January 2019. The levels of Th17, Treg and their TFs [forkhead box protein P3 (Foxp3), retinoid acid receptor-related orphan receptor gamma t (RORγt)] and secreted inflammatory factors (IFs) [interleukin-17 (IL-17), interleukin-22 (IL-22)] were detected in the peripheral blood (PB) of both groups, and the TFs' phosphorylated protein expression was observed by Western blot. Further, the correlation of TFs with patients' pathological features was analyzed. Finally, a 3-year prognostic follow-up was performed on CRC patients. Receiver operating characteristic (ROC) determined the predictive value of Th17/Treg on the prognostic mortality of patients.

Results: Peripheral blood Th17 and Treg showed higher levels in the EG than in the CG, demonstrating excellent diagnostic effects on CRC (P<0.05). The EG also exhibited reduced Foxp3 and p-Foxp3 protein expression, and elevated RORγt and p-RORγt levels compared with the CG (all P<0.0001). In addition, the EG exhibited statistically higher IL-17 and IL-22 levels than the CG (all P<0.05). Further, the analysis of pathological features revealed close correlations of Th17/Treg, RORγt and Foxp3 with tumor size, TNM staging, degree of differentiation, and lymph node metastasis (LNM) of CRC patients (all P<0.001). Finally, the prognostic follow-up results identified that TNM staging, degree of differentiation, LNM, RORγt, Th17 and Treg were independent risk factors for prognostic mortality of CRC patients, while Foxp3 was an independent protective factor (all P<0.001).

Conclusion: Th17/Treg associated TFs are of great significance for the prognosis evaluation of CRC, the imbalance of which can cause aggravation of the inflammatory reaction and promote malignancy of CRC.

目的分析Th17/Treg相关转录因子(TFs)与结直肠癌(CRC)临床病理特征的相关性及其预后意义:本研究共纳入2017年6月至2019年1月期间在德清县人民医院就诊的56例CRC患者(实验组,EG)和50例健康对照组(对照组,CG)。检测两组患者外周血(PB)中Th17、Treg及其TFs[叉头盒蛋白P3(Foxp3)、视黄酸受体相关孤儿受体γt(RORγt)]和分泌性炎症因子(IFs)[白细胞介素-17(IL-17)、白细胞介素-22(IL-22)]的水平,并通过Western印迹观察TFs磷酸化蛋白的表达。此外,还分析了 TFs 与患者病理特征的相关性。最后,对 CRC 患者进行了为期 3 年的预后随访。接收者操作特征(ROC)确定了Th17/Treg对患者预后死亡率的预测价值:结果:外周血 Th17 和 Treg 在 EG 中的水平高于 CG,显示出对 CRC 极佳的诊断效果:Th17/Treg相关TFs对CRC的预后评估具有重要意义,其失衡会导致炎症反应加重,促进CRC恶变。
{"title":"Correlation of Th17/Treg associated transcription factors with clinicopathological features of colorectal cancer and their prognostic significance.","authors":"Jianqiang Pan, Zhengrong Su, Zhihong Liu, Xingwei Zhong","doi":"10.62347/IOAM8718","DOIUrl":"https://doi.org/10.62347/IOAM8718","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the correlation of Th17/Treg associated transcription factors (TFs) with clinicopathological features of colorectal cancer (CRC) and their prognostic significance.</p><p><strong>Methods: </strong>This research enrolled 56 CRC patients (experimental group, EG) and 50 healthy controls (control group, CG), who presented to Deqing People's Hospital between June 2017 and January 2019. The levels of Th17, Treg and their TFs [forkhead box protein P3 (Foxp3), retinoid acid receptor-related orphan receptor gamma t (RORγt)] and secreted inflammatory factors (IFs) [interleukin-17 (IL-17), interleukin-22 (IL-22)] were detected in the peripheral blood (PB) of both groups, and the TFs' phosphorylated protein expression was observed by Western blot. Further, the correlation of TFs with patients' pathological features was analyzed. Finally, a 3-year prognostic follow-up was performed on CRC patients. Receiver operating characteristic (ROC) determined the predictive value of Th17/Treg on the prognostic mortality of patients.</p><p><strong>Results: </strong>Peripheral blood Th17 and Treg showed higher levels in the EG than in the CG, demonstrating excellent diagnostic effects on CRC (<i>P</i><0.05). The EG also exhibited reduced Foxp3 and p-Foxp3 protein expression, and elevated RORγt and p-RORγt levels compared with the CG (all <i>P</i><0.0001). In addition, the EG exhibited statistically higher IL-17 and IL-22 levels than the CG (all <i>P</i><0.05). Further, the analysis of pathological features revealed close correlations of Th17/Treg, RORγt and Foxp3 with tumor size, TNM staging, degree of differentiation, and lymph node metastasis (LNM) of CRC patients (all <i>P</i><0.001). Finally, the prognostic follow-up results identified that TNM staging, degree of differentiation, LNM, RORγt, Th17 and Treg were independent risk factors for prognostic mortality of CRC patients, while Foxp3 was an independent protective factor (all <i>P</i><0.001).</p><p><strong>Conclusion: </strong>Th17/Treg associated TFs are of great significance for the prognosis evaluation of CRC, the imbalance of which can cause aggravation of the inflammatory reaction and promote malignancy of CRC.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparative study of the efficacy and safety of PD-1/L1 inhibitor and platinum-containing dual-agent chemotherapy in patients with advanced non-small cell lung cancer resistant to EGFR-TKIs. 对表皮生长因子受体-TKIs耐药的晚期非小细胞肺癌患者使用PD-1/L1抑制剂和含铂双药化疗的疗效和安全性比较研究。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.62347/FEVG6730
Chunhui Shi, Xiaochun Liu, Jing Zhao, Wenjiang Xu, Rui Zhang, Zhongqin He

Objective: To assess the efficacy and safety of combining Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1) inhibitors with platinum-containing chemotherapy for treating late-stage Non-Small Cell Lung Cancer (NSCLC) patients who have developed resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs).

Methods: A retrospective analysis was conducted at Baoji Traditional Chinese Medicine Hospital involving 133 patients with advanced NSCLC who had shown resistance to EGFR-TKIs and were treated from October 2018 to May 2021. The cohort was categorized into two groups: one treated with immune checkpoint inhibitors (ICIs) plus chemotherapy and antiangiogenic agents (ICIs+BCP group), and the other treated with ICIs alone (ICIs group). Baseline data collected included demographic factors, smoking status, PD-L1 Tumor Proportion Score (TPS), EGFR mutation, Eastern Cooperative Oncology Group (ECOG) score, and routine blood markers prior to second-line therapy. Computed Tomography (CT) scans were performed every two treatment courses to evaluate the treatment efficacy.

Results: The ICIs+BCP group exhibited a statistically significant improvement in Overall Survival (OS) compared to the ICIs group (P=0.001). Cox survival analysis uncovered age (P=0.012), PD-L1 TPS expression (P<0.001), treatment regimen (P=0.006), Neutrophil-to-Lymphocyte Ratio (NLR) (P=0.024), and Platelet-to-Lymphocyte Ratio (PLR) (P=0.005) as independent factors influencing OS in patients with advanced NSCLC resistant to primary-line EGFR-TKI therapy. The nomogram model, based on these prognostic factors, exhibited Area Under the Curve (AUC) values of 0.823 and 0.769, indicating its predictive accuracy for 1-year and 2-year survival, respectively.

Conclusion: Combining ICIs with BCP prolongs OS in patients with NSCLC resistant to EGFR-TKIs. This study underscores the importance of personalized treatment plans and biomarker evaluations to improve outcomes in drug-resistant cases.

目的评估程序性死亡-1/程序性死亡配体1(PD-1/L1)抑制剂联合含铂化疗治疗对表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKIs)耐药的晚期非小细胞肺癌(NSCLC)患者的疗效和安全性:宝鸡市中医医院对2018年10月至2021年5月期间接受治疗的133例EGFR-TKIs耐药的晚期NSCLC患者进行了回顾性分析。队列分为两组:一组接受免疫检查点抑制剂(ICIs)加化疗和抗血管生成药物治疗(ICIs+BCP组),另一组仅接受ICIs治疗(ICIs组)。收集的基线数据包括人口统计学因素、吸烟状况、PD-L1肿瘤比例评分(TPS)、表皮生长因子受体突变、东部合作肿瘤学组(ECOG)评分以及二线治疗前的常规血液指标。每两个疗程进行一次计算机断层扫描(CT),以评估疗效:与 ICIs 组相比,ICIs+BCP 组的总生存期(OS)有显著的统计学改善(P=0.001)。Cox生存分析揭示了年龄(P=0.012)、PD-L1 TPS表达(PConclusion:ICIs与BCP联合治疗可延长对EGFR-TKIs耐药的NSCLC患者的OS。这项研究强调了个性化治疗方案和生物标志物评估对改善耐药病例预后的重要性。
{"title":"A comparative study of the efficacy and safety of PD-1/L1 inhibitor and platinum-containing dual-agent chemotherapy in patients with advanced non-small cell lung cancer resistant to EGFR-TKIs.","authors":"Chunhui Shi, Xiaochun Liu, Jing Zhao, Wenjiang Xu, Rui Zhang, Zhongqin He","doi":"10.62347/FEVG6730","DOIUrl":"https://doi.org/10.62347/FEVG6730","url":null,"abstract":"<p><strong>Objective: </strong>To assess the efficacy and safety of combining Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1) inhibitors with platinum-containing chemotherapy for treating late-stage Non-Small Cell Lung Cancer (NSCLC) patients who have developed resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs).</p><p><strong>Methods: </strong>A retrospective analysis was conducted at Baoji Traditional Chinese Medicine Hospital involving 133 patients with advanced NSCLC who had shown resistance to EGFR-TKIs and were treated from October 2018 to May 2021. The cohort was categorized into two groups: one treated with immune checkpoint inhibitors (ICIs) plus chemotherapy and antiangiogenic agents (ICIs+BCP group), and the other treated with ICIs alone (ICIs group). Baseline data collected included demographic factors, smoking status, PD-L1 Tumor Proportion Score (TPS), EGFR mutation, Eastern Cooperative Oncology Group (ECOG) score, and routine blood markers prior to second-line therapy. Computed Tomography (CT) scans were performed every two treatment courses to evaluate the treatment efficacy.</p><p><strong>Results: </strong>The ICIs+BCP group exhibited a statistically significant improvement in Overall Survival (OS) compared to the ICIs group (P=0.001). Cox survival analysis uncovered age (P=0.012), PD-L1 TPS expression (P<0.001), treatment regimen (P=0.006), Neutrophil-to-Lymphocyte Ratio (NLR) (P=0.024), and Platelet-to-Lymphocyte Ratio (PLR) (P=0.005) as independent factors influencing OS in patients with advanced NSCLC resistant to primary-line EGFR-TKI therapy. The nomogram model, based on these prognostic factors, exhibited Area Under the Curve (AUC) values of 0.823 and 0.769, indicating its predictive accuracy for 1-year and 2-year survival, respectively.</p><p><strong>Conclusion: </strong>Combining ICIs with BCP prolongs OS in patients with NSCLC resistant to EGFR-TKIs. This study underscores the importance of personalized treatment plans and biomarker evaluations to improve outcomes in drug-resistant cases.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salvia miltiorrhiza bge. f. alba ameliorates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease via the STING pathway. 丹参(Salvia miltiorrhiza bge. f. alba)通过 STING 途径改善 2 型糖尿病相关的非酒精性脂肪肝。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.62347/XUNO9933
Donghui Huang, Fuyan Bai, Tingting Hu, Jing Li, Guoning Wang, Chengsheng Wu

Objective: To elucidate the functional role and underlying mechanism of Salvia miltiorrhiza bge. f. alba (SMBFA) in patients with type 2 diabetes mellitus (T2DM) accompanied by non-alcoholic fatty liver disease (NAFLD).

Methods: A retrospective analysis was conducted on 90 patients with T2DM-NAFLD who met the inclusion criteria. The control group was comprised of 45 patients treated with Fenofibrate, while the observation group consisted of 45 patients who received SMBFA in addition to the control treatment. An in vivo mouse model of T2DM-NAFLD was established using a high-fat diet combined with streptozotocin. Serum levels of fasting plasma glucose (FPG), 2-hour postprandial glucose (2h PG), hemoglobin A1c (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR), total cholesterol (TC), and triglyceride (TG) were measured in both patients and mice using an automated biochemical analyzer. Liver indices and function were also evaluated. ELISA assays were performed to quantify inflammatory cytokine levels. Western blotting was utilized to assess the protein levels related to the stimulator of interferon genes (STING)-interferon regulatory factor 3 (IRF3) pathway.

Results: After treatment, significant reductions in blood glucose indices, HOMA-IR, lipid metabolism markers, liver function indices, and inflammatory cytokines were observed in both groups of T2DM-NAFLD patients. Notably, the decreases were more pronounced in the observation group compared to the control group. Similarly, in T2DM-NAFLD mouse models, the levels of these parameters were significantly lower in the observation group than in the normal control (NC) group. Additionally, SMBFA suppressed the elevated levels of STING, p-IRF3, and p-TANK-binding kinase 1 in the T2DM-NAFLD mice.

Conclusion: SMBFA exhibits the potential to regulate glucose and lipid metabolism, inhibit insulin resistance, and protect liver function by modulating the STING signaling pathway.

目的阐明丹参(SMBFA)在伴有非酒精性脂肪肝(NAFLD)的2型糖尿病(T2DM)患者中的功能作用和潜在机制:对符合纳入标准的 90 名 T2DM-NAFLD 患者进行了回顾性分析。对照组由 45 名接受非诺贝特治疗的患者组成,观察组由 45 名在接受对照组治疗的同时接受 SMBFA 治疗的患者组成。利用高脂饮食和链脲佐菌素建立了 T2DM-NAFLD 小鼠体内模型。使用自动生化分析仪测量了患者和小鼠的血清空腹血浆葡萄糖(FPG)、餐后 2 小时血糖(2h PG)、血红蛋白 A1c(HbA1c)、胰岛素抵抗稳态模型评估(HOMA-IR)、总胆固醇(TC)和甘油三酯(TG)水平。还对肝脏指数和功能进行了评估。酶联免疫吸附试验(ELISA)用于量化炎症细胞因子水平。用 Western 印迹法评估与干扰素基因刺激因子(STING)-干扰素调节因子 3(IRF3)通路相关的蛋白质水平:结果:治疗后,两组 T2DM-NAFLD 患者的血糖指数、HOMA-IR、脂代谢指标、肝功能指数和炎症细胞因子均明显下降。值得注意的是,与对照组相比,观察组的降幅更为明显。同样,在 T2DM-NAFLD 小鼠模型中,观察组的这些参数水平也明显低于正常对照(NC)组。此外,SMBFA 还能抑制 T2DM-NAFLD 小鼠体内 STING、p-IRF3 和 p-TANK 结合激酶 1 水平的升高:结论:SMBFA 具有通过调节 STING 信号通路调节葡萄糖和脂质代谢、抑制胰岛素抵抗和保护肝功能的潜力。
{"title":"Salvia miltiorrhiza bge. f. alba ameliorates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease via the STING pathway.","authors":"Donghui Huang, Fuyan Bai, Tingting Hu, Jing Li, Guoning Wang, Chengsheng Wu","doi":"10.62347/XUNO9933","DOIUrl":"https://doi.org/10.62347/XUNO9933","url":null,"abstract":"<p><strong>Objective: </strong>To elucidate the functional role and underlying mechanism of Salvia miltiorrhiza bge. f. alba (SMBFA) in patients with type 2 diabetes mellitus (T2DM) accompanied by non-alcoholic fatty liver disease (NAFLD).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 90 patients with T2DM-NAFLD who met the inclusion criteria. The control group was comprised of 45 patients treated with Fenofibrate, while the observation group consisted of 45 patients who received SMBFA in addition to the control treatment. An in vivo mouse model of T2DM-NAFLD was established using a high-fat diet combined with streptozotocin. Serum levels of fasting plasma glucose (FPG), 2-hour postprandial glucose (2h PG), hemoglobin A1c (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR), total cholesterol (TC), and triglyceride (TG) were measured in both patients and mice using an automated biochemical analyzer. Liver indices and function were also evaluated. ELISA assays were performed to quantify inflammatory cytokine levels. Western blotting was utilized to assess the protein levels related to the stimulator of interferon genes (STING)-interferon regulatory factor 3 (IRF3) pathway.</p><p><strong>Results: </strong>After treatment, significant reductions in blood glucose indices, HOMA-IR, lipid metabolism markers, liver function indices, and inflammatory cytokines were observed in both groups of T2DM-NAFLD patients. Notably, the decreases were more pronounced in the observation group compared to the control group. Similarly, in T2DM-NAFLD mouse models, the levels of these parameters were significantly lower in the observation group than in the normal control (NC) group. Additionally, SMBFA suppressed the elevated levels of STING, p-IRF3, and p-TANK-binding kinase 1 in the T2DM-NAFLD mice.</p><p><strong>Conclusion: </strong>SMBFA exhibits the potential to regulate glucose and lipid metabolism, inhibit insulin resistance, and protect liver function by modulating the STING signaling pathway.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive multi-omics analysis and prognostic significance of fibroblast growth factor binding protein 1 (FGFBP1) in pancreatic adenocarcinoma. 胰腺腺癌中成纤维细胞生长因子结合蛋白1(FGFBP1)的多组学综合分析及其预后意义
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.62347/NCRX9798
Zicheng Shao, Mostafa A Abdel-Maksoud, Ibrahim A Saleh, Jehad S Al-Hawadi, Naser Zomot, Saeedah Musaed Almutairi, Jie Chen

Background: Pancreatic adenocarcinoma (PAAD) is a highly aggressive cancer with poor prognosis and limited therapeutic options. Identifying molecular markers and understanding their role in PAAD pathogenesis is crucial for developing targeted therapies. This study integrates bioinformatics and molecular experiments to investigate the diagnostic, prognostic, and therapeutic significance of FGFBP1 in PAAD.

Methods: UALCAN, TNMplot, OncoDB, GEPIA2, HPA, GSCA, KM Plotter, TISIDB, TISCH2, CancerSEA, STRING, DAVID, cell culture, RT-qPCR analysis, western blot analysis, colony formation, cell proliferation, and wound healing assays.

Results: Expression analyses revealed a significantly elevated FGFBP1 levels in PAAD tissues compared to normal samples. Promoter methylation analysis indicated lower methylation levels in PAAD, inversely correlated with FGFBP1 expression, suggesting epigenetic regulation. Genetic alteration analysis showed that FGFBP1 is not significantly affected by single nucleotide variants, but copy number variations are present without impacting mRNA expression. Survival analysis using KM plotter demonstrated that high FGFBP1 expression is associated with poor overall and disease-free survival. A Cox regression-based prognostic model confirmed the negative impact of elevated FGFBP1 on patient outcomes. Correlation analysis with immune-related factors indicated that FGFBP1 may contribute to an immunosuppressive tumor microenvironment, affecting immune cell infiltration and function. Single-cell analysis highlighted FGFBP1 expression in malignant, endothelial, and fibroblast cells within the tumor microenvironment. Gene enrichment analysis revealed FGFBP1's involvement in various biological processes and pathways related to cancer progression. Experimental validation using RT-qPCR confirmed high FGFBP1 expression in PAAD cell lines. FGFBP1 knockdown in HEK293T cells significantly reduced cell proliferation, colony formation, and migration.

Conclusion: These findings suggest that FGFBP1 plays a critical role in PAAD pathogenesis and could serve as a potential therapeutic target for improving patient outcomes.

背景:胰腺腺癌(PAAD)是一种侵袭性极强的癌症,预后不良,治疗方案有限。确定分子标记物并了解它们在 PAAD 发病机制中的作用对于开发靶向疗法至关重要。本研究整合了生物信息学和分子实验,研究 FGFBP1 在 PAAD 中的诊断、预后和治疗意义:UALCAN、TNMplot、OncoDB、GEPIA2、HPA、GSCA、KM Plotter、TISIDB、TISCH2、CancerSEA、STRING、DAVID、细胞培养、RT-qPCR分析、Western印迹分析、集落形成、细胞增殖和伤口愈合试验:结果:表达分析表明,与正常样本相比,PAAD 组织中的 FGFBP1 水平明显升高。启动子甲基化分析表明 PAAD 中甲基化水平较低,与 FGFBP1 表达成反比,提示存在表观遗传调控。遗传变异分析表明,单核苷酸变异对 FGFBP1 的影响不大,但存在拷贝数变异,但不影响 mRNA 的表达。使用 KM plotter 进行的生存期分析表明,FGFBP1 的高表达与总生存期和无病生存期差有关。基于 Cox 回归的预后模型证实了 FGFBP1 升高对患者预后的负面影响。与免疫相关因素的相关性分析表明,FGFBP1可能会造成免疫抑制性肿瘤微环境,影响免疫细胞的浸润和功能。单细胞分析强调了FGFBP1在肿瘤微环境中恶性细胞、内皮细胞和成纤维细胞中的表达。基因富集分析显示,FGFBP1 参与了与癌症进展相关的各种生物过程和通路。使用 RT-qPCR 进行的实验验证证实了 PAAD 细胞系中 FGFBP1 的高表达。在 HEK293T 细胞中敲除 FGFBP1 能显著减少细胞增殖、集落形成和迁移:这些研究结果表明,FGFBP1 在 PAAD 发病机制中起着关键作用,可作为改善患者预后的潜在治疗靶点。
{"title":"Comprehensive multi-omics analysis and prognostic significance of fibroblast growth factor binding protein 1 (FGFBP1) in pancreatic adenocarcinoma.","authors":"Zicheng Shao, Mostafa A Abdel-Maksoud, Ibrahim A Saleh, Jehad S Al-Hawadi, Naser Zomot, Saeedah Musaed Almutairi, Jie Chen","doi":"10.62347/NCRX9798","DOIUrl":"https://doi.org/10.62347/NCRX9798","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic adenocarcinoma (PAAD) is a highly aggressive cancer with poor prognosis and limited therapeutic options. Identifying molecular markers and understanding their role in PAAD pathogenesis is crucial for developing targeted therapies. This study integrates bioinformatics and molecular experiments to investigate the diagnostic, prognostic, and therapeutic significance of FGFBP1 in PAAD.</p><p><strong>Methods: </strong>UALCAN, TNMplot, OncoDB, GEPIA2, HPA, GSCA, KM Plotter, TISIDB, TISCH2, CancerSEA, STRING, DAVID, cell culture, RT-qPCR analysis, western blot analysis, colony formation, cell proliferation, and wound healing assays.</p><p><strong>Results: </strong>Expression analyses revealed a significantly elevated FGFBP1 levels in PAAD tissues compared to normal samples. Promoter methylation analysis indicated lower methylation levels in PAAD, inversely correlated with FGFBP1 expression, suggesting epigenetic regulation. Genetic alteration analysis showed that FGFBP1 is not significantly affected by single nucleotide variants, but copy number variations are present without impacting mRNA expression. Survival analysis using KM plotter demonstrated that high FGFBP1 expression is associated with poor overall and disease-free survival. A Cox regression-based prognostic model confirmed the negative impact of elevated FGFBP1 on patient outcomes. Correlation analysis with immune-related factors indicated that FGFBP1 may contribute to an immunosuppressive tumor microenvironment, affecting immune cell infiltration and function. Single-cell analysis highlighted FGFBP1 expression in malignant, endothelial, and fibroblast cells within the tumor microenvironment. Gene enrichment analysis revealed FGFBP1's involvement in various biological processes and pathways related to cancer progression. Experimental validation using RT-qPCR confirmed high FGFBP1 expression in PAAD cell lines. FGFBP1 knockdown in HEK293T cells significantly reduced cell proliferation, colony formation, and migration.</p><p><strong>Conclusion: </strong>These findings suggest that FGFBP1 plays a critical role in PAAD pathogenesis and could serve as a potential therapeutic target for improving patient outcomes.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of general anesthesia drugs on GFAP/Iba-1 expression: a meta-analysis. 全身麻醉药物对 GFAP/Iba-1 表达的影响:一项荟萃分析。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.62347/DUFQ3980
Dianjun Liu, Xiangwen Yao, Hao Zhang

Glial fibrillary acidic protein (GFAP) is a marker associated with astrocyte activation and plays a role in various pathologic processes, including traumatic brain injury, stroke, and neurodegenerative diseases. Interacting boson approximation (Iba-1) is a marker protein for microglia, which are important in neuroinflammatory responses. This meta-analysis aimed to investigate the impact of general anesthetics on the expression of GFAP and Iba-1 in animal models. A meta-analysis was conducted using databases such as PubMed, EMBASE, Springer, and Web of Science. The quality of the selected publications was estimated using the SYRCLE guidelines to ensure credibility and consistency of the research. Continuous variables were measured using mean difference or standardized mean difference (SMD), with a 95% confidence interval (CI) calculated. Ten randomized controlled animal experiments were included in this analysis, utilizing different general anesthetics such as sevoflurane and propofol compared to untreated control groups. The results consistently demonstrated a significant increase in GFAP (SMD = 0.41, 95% CI: 0.09, 0.72, P = 0.01) and Iba-1 (SMD = 0.43, 95% CI: 0.04, 0.83, P = 0.03) expression in the general anesthetic-treated groups, suggesting a neuroinflammatory response induced by these agents. Assessment of publication bias revealed no significant bias in the included studies. This meta-analysis highlights the impact of general anesthetics on GFAP expression in animal models, emphasizing the importance of understanding the neuroinflammatory response associated with anesthesia administration. Further research is warranted to elucidate the underlying molecular pathways and explore possible therapeutic interventions to mitigate adverse effects associated with anesthesia administration.

胶质纤维酸性蛋白(GFAP)是一种与星形胶质细胞活化相关的标志物,在包括脑外伤、中风和神经退行性疾病在内的各种病理过程中发挥作用。相互作用玻色子近似(Iba-1)是小胶质细胞的标志蛋白,在神经炎症反应中起着重要作用。这项荟萃分析旨在研究全身麻醉剂对动物模型中 GFAP 和 Iba-1 表达的影响。荟萃分析使用了 PubMed、EMBASE、Springer 和 Web of Science 等数据库。采用 SYRCLE 指南对所选出版物的质量进行了评估,以确保研究的可信度和一致性。连续变量采用平均差或标准化平均差(SMD)进行测量,并计算出 95% 的置信区间(CI)。本分析包括十项随机对照动物实验,与未经处理的对照组相比,这些实验使用了不同的全身麻醉剂,如七氟醚和异丙酚。结果一致表明,在全身麻醉剂治疗组中,GFAP(SMD = 0.41,95% CI:0.09,0.72,P = 0.01)和 Iba-1 (SMD = 0.43,95% CI:0.04,0.83,P = 0.03)表达明显增加,这表明这些药物诱发了神经炎症反应。对发表偏倚的评估显示,纳入的研究中没有明显的偏倚。这项荟萃分析强调了全身麻醉剂对动物模型中 GFAP 表达的影响,强调了了解与麻醉用药相关的神经炎症反应的重要性。我们有必要开展进一步的研究,以阐明潜在的分子通路并探索可能的治疗干预措施,从而减轻与麻醉相关的不良反应。
{"title":"Effect of general anesthesia drugs on GFAP/Iba-1 expression: a meta-analysis.","authors":"Dianjun Liu, Xiangwen Yao, Hao Zhang","doi":"10.62347/DUFQ3980","DOIUrl":"https://doi.org/10.62347/DUFQ3980","url":null,"abstract":"<p><p>Glial fibrillary acidic protein (GFAP) is a marker associated with astrocyte activation and plays a role in various pathologic processes, including traumatic brain injury, stroke, and neurodegenerative diseases. Interacting boson approximation (Iba-1) is a marker protein for microglia, which are important in neuroinflammatory responses. This meta-analysis aimed to investigate the impact of general anesthetics on the expression of GFAP and Iba-1 in animal models. A meta-analysis was conducted using databases such as PubMed, EMBASE, Springer, and Web of Science. The quality of the selected publications was estimated using the SYRCLE guidelines to ensure credibility and consistency of the research. Continuous variables were measured using mean difference or standardized mean difference (SMD), with a 95% confidence interval (CI) calculated. Ten randomized controlled animal experiments were included in this analysis, utilizing different general anesthetics such as sevoflurane and propofol compared to untreated control groups. The results consistently demonstrated a significant increase in GFAP (SMD = 0.41, 95% CI: 0.09, 0.72, P = 0.01) and Iba-1 (SMD = 0.43, 95% CI: 0.04, 0.83, P = 0.03) expression in the general anesthetic-treated groups, suggesting a neuroinflammatory response induced by these agents. Assessment of publication bias revealed no significant bias in the included studies. This meta-analysis highlights the impact of general anesthetics on GFAP expression in animal models, emphasizing the importance of understanding the neuroinflammatory response associated with anesthesia administration. Further research is warranted to elucidate the underlying molecular pathways and explore possible therapeutic interventions to mitigate adverse effects associated with anesthesia administration.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of NT-proBNP and uric acid in acute ST-segment elevation myocardial infarction patients after complete revascularization. 完全血运重建后急性 ST 段抬高型心肌梗死患者 NT-proBNP 和尿酸的预后价值。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.62347/VQWS9174
Li Kang, Denghai Xie, Dandan Chen, Chunwei Wu

Objectives: To explore the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and uric acid (UA) in acute ST-segment elevation myocardial infarction (STEMI) patients after complete revascularization (CR).

Methods: The clinical and physical data from 125 acute STEMI patients (research group) who underwent CR between December 2017 and December 2020 and 60 healthy individuals (control group) who concurrently underwent physical examinations in the Affiliated Hospital of Guizhou Medical University were retrospectively analyzed in this study. Serum samples were collected from both groups to determine the levels of NT-proBNP and UA. The 3-year follow-up data of acute STEMI patients were collected, which were used to group the patients into a good and a poor prognosis group based on their prognoses to comparatively analyze NT-proBNP and UA levels. Receiver operating characteristic (ROC) curves were drawn to analyze the prognostic value of NT-proBNP and UA in STEMI patients following CR, and survival curves were plotted to observe their influences on patients' 3-year overall survival (OS). Meanwhile, a univariate analysis was conducted to identify factors associated with the 3-year OS of acute STEMI patients after CR.

Results: The data showed significantly higher expression levels of serum NT-proBNP and UA in acute STEMI patients than in the controls. Besides, the good prognosis group exhibited markedly lower serum NT-proBNP and UA levels than the poor prognosis group. The areas under the curve (AUCs) of NT-proBNP and UA in predicting the prognosis of acute STEMI patients after CR were all above 0.700, and the AUC of their combined detection reached over 0.800. In addition, high serum NT-proBNP and UA levels were strongly associated with lower 3-year OS rates. As indicated by the univariate analysis, a history of smoking and alcoholism as well as high NT-proBNP and UA levels were closely associated with 3-year OS in acute STEMI patients after CR.

Conclusions: NT-proBNP and UA have promising prognostic value in acute STEMI after CR.

目的探讨N末端前B型利钠肽(NT-proBNP)和尿酸(UA)在完全血管再通(CR)后急性ST段抬高型心肌梗死(STEMI)患者中的预后价值:本研究回顾性分析了贵州医科大学附属医院2017年12月至2020年12月期间接受CR治疗的125例急性STEMI患者(研究组)和同时接受体检的60例健康人(对照组)的临床和体格检查数据。收集两组患者的血清样本,以测定NT-proBNP和UA的水平。收集急性 STEMI 患者 3 年的随访数据,根据预后情况将患者分为预后良好组和预后不良组,对 NT-proBNP 和 UA 水平进行比较分析。绘制接收者操作特征曲线(ROC),以分析 CR 后 STEMI 患者 NT-proBNP 和 UA 的预后价值,并绘制生存曲线,以观察它们对患者 3 年总生存率(OS)的影响。同时,进行单变量分析以确定与急性 STEMI 患者 CR 后 3 年 OS 相关的因素:数据显示,急性 STEMI 患者血清 NT-proBNP 和 UA 的表达水平明显高于对照组。此外,预后良好组的血清 NT-proBNP 和 UA 水平明显低于预后不良组。在预测 CR 后急性 STEMI 患者预后方面,NT-proBNP 和 UA 的曲线下面积(AUC)均在 0.700 以上,两者联合检测的 AUC 达到 0.800 以上。此外,高血清 NT-proBNP 和 UA 水平与较低的 3 年 OS 率密切相关。单变量分析表明,吸烟和酗酒史以及高NT-proBNP和UA水平与急性STEMI患者CR后的3年OS密切相关:NT-proBNP和UA对急性STEMI患者CR后的预后具有重要价值。
{"title":"Prognostic value of NT-proBNP and uric acid in acute ST-segment elevation myocardial infarction patients after complete revascularization.","authors":"Li Kang, Denghai Xie, Dandan Chen, Chunwei Wu","doi":"10.62347/VQWS9174","DOIUrl":"https://doi.org/10.62347/VQWS9174","url":null,"abstract":"<p><strong>Objectives: </strong>To explore the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and uric acid (UA) in acute ST-segment elevation myocardial infarction (STEMI) patients after complete revascularization (CR).</p><p><strong>Methods: </strong>The clinical and physical data from 125 acute STEMI patients (research group) who underwent CR between December 2017 and December 2020 and 60 healthy individuals (control group) who concurrently underwent physical examinations in the Affiliated Hospital of Guizhou Medical University were retrospectively analyzed in this study. Serum samples were collected from both groups to determine the levels of NT-proBNP and UA. The 3-year follow-up data of acute STEMI patients were collected, which were used to group the patients into a good and a poor prognosis group based on their prognoses to comparatively analyze NT-proBNP and UA levels. Receiver operating characteristic (ROC) curves were drawn to analyze the prognostic value of NT-proBNP and UA in STEMI patients following CR, and survival curves were plotted to observe their influences on patients' 3-year overall survival (OS). Meanwhile, a univariate analysis was conducted to identify factors associated with the 3-year OS of acute STEMI patients after CR.</p><p><strong>Results: </strong>The data showed significantly higher expression levels of serum NT-proBNP and UA in acute STEMI patients than in the controls. Besides, the good prognosis group exhibited markedly lower serum NT-proBNP and UA levels than the poor prognosis group. The areas under the curve (AUCs) of NT-proBNP and UA in predicting the prognosis of acute STEMI patients after CR were all above 0.700, and the AUC of their combined detection reached over 0.800. In addition, high serum NT-proBNP and UA levels were strongly associated with lower 3-year OS rates. As indicated by the univariate analysis, a history of smoking and alcoholism as well as high NT-proBNP and UA levels were closely associated with 3-year OS in acute STEMI patients after CR.</p><p><strong>Conclusions: </strong>NT-proBNP and UA have promising prognostic value in acute STEMI after CR.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of multi-disciplinary team nursing model enhances recovery after surgery for total hip arthroplasty and total knee arthroplasty. 多学科团队护理模式的应用促进了全髋关节置换术和全膝关节置换术术后的恢复。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.62347/BHGS1734
Xiudan Zhou, Tianfei Wei

Aim: To explore the effect of a multidisciplinary team (MDT) nursing model based on enhanced recovery after surgery (ERAS) in total hip arthroplasty (THA)/total knee arthroplasty (TKA) and evaluate its application in the perioperative period of patients.

Methods: A retrospective analysis was conducted on 100 patients with THA/TKA treated at Shaoxing Second Hospital Medical Community General Hospital from January 2021 to December 2023. The patients were divided into an observation group (n = 50) and a control group (n = 50) based on the nursing method employed. The control group received traditional perioperative nursing, while the observation group received an MDT nursing model intervention based on the ERAS concept. Visual analogue scale (VAS) scores were recorded at 6, 24, and 72 hours post-surgery. Additionally, postoperative activities, hospitalization duration, and postoperative complications were documented. Differences in knee joint range of motion (ROM), hip Harris score, psychological stress response score, and quality of life score between the two groups before and one month after surgery were analyzed.

Results: At 6, 24, and 72 hours post-surgery, patients in the observation group had significantly lower VAS scores compared to those in the control group (all P < 0.05). The observation group had an earlier first-time mobilization (P < 0.05). The length of hospitalization and hospitalization cost were significantly lower in the observation group than in the control group (both P < 0.05). The incidence rates of postoperative adverse reactions were 22.00% in the control group and 6.00% in the observation group (P < 0.05). One month post-surgery, the observation group showed significantly greater ROM, lower psychological stress and reaction scores, and higher Harris score and quality of life score compared to the control group (all P < 0.05).

Conclusion: The MDT nursing model based on ERAS concept for THA/TKA perioperative patients effectively alleviates postoperative pain, promotes early activity, shortens hospital stay, reduces hospital cost, decreases the incidence of complications, restores joint function, enhances quality of life, and reduces psychological stress.

目的:探讨基于增强术后恢复(ERAS)的多学科团队(MDT)护理模式在全髋关节置换术(THA)/全膝关节置换术(TKA)中的应用效果,并评估其在患者围手术期的应用情况:方法:对2021年1月至2023年12月在绍兴市第二医院医共体综合医院接受治疗的100例THA/TKA患者进行回顾性分析。根据采用的护理方法将患者分为观察组(n = 50)和对照组(n = 50)。对照组接受传统的围手术期护理,而观察组则接受基于ERAS理念的MDT护理模式干预。记录术后 6、24 和 72 小时的视觉模拟量表(VAS)评分。此外,还记录了术后活动、住院时间和术后并发症。分析了两组患者术前和术后一个月的膝关节活动范围(ROM)、髋关节哈里斯评分、心理应激反应评分和生活质量评分的差异:术后6、24和72小时,观察组患者的VAS评分明显低于对照组(P均<0.05)。观察组首次活动时间更早(P < 0.05)。观察组的住院时间和住院费用明显低于对照组(均P < 0.05)。对照组术后不良反应发生率为22.00%,观察组为6.00%(P < 0.05)。术后一个月,观察组与对照组相比,ROM明显增加,心理压力和反应评分降低,Harris评分和生活质量评分提高(均P < 0.05):基于ERAS理念的MDT护理模式对THA/TKA围手术期患者能有效缓解术后疼痛,促进早期活动,缩短住院时间,降低住院费用,减少并发症的发生率,恢复关节功能,提高生活质量,减轻心理压力。
{"title":"Application of multi-disciplinary team nursing model enhances recovery after surgery for total hip arthroplasty and total knee arthroplasty.","authors":"Xiudan Zhou, Tianfei Wei","doi":"10.62347/BHGS1734","DOIUrl":"https://doi.org/10.62347/BHGS1734","url":null,"abstract":"<p><strong>Aim: </strong>To explore the effect of a multidisciplinary team (MDT) nursing model based on enhanced recovery after surgery (ERAS) in total hip arthroplasty (THA)/total knee arthroplasty (TKA) and evaluate its application in the perioperative period of patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 100 patients with THA/TKA treated at Shaoxing Second Hospital Medical Community General Hospital from January 2021 to December 2023. The patients were divided into an observation group (n = 50) and a control group (n = 50) based on the nursing method employed. The control group received traditional perioperative nursing, while the observation group received an MDT nursing model intervention based on the ERAS concept. Visual analogue scale (VAS) scores were recorded at 6, 24, and 72 hours post-surgery. Additionally, postoperative activities, hospitalization duration, and postoperative complications were documented. Differences in knee joint range of motion (ROM), hip Harris score, psychological stress response score, and quality of life score between the two groups before and one month after surgery were analyzed.</p><p><strong>Results: </strong>At 6, 24, and 72 hours post-surgery, patients in the observation group had significantly lower VAS scores compared to those in the control group (all P < 0.05). The observation group had an earlier first-time mobilization (P < 0.05). The length of hospitalization and hospitalization cost were significantly lower in the observation group than in the control group (both P < 0.05). The incidence rates of postoperative adverse reactions were 22.00% in the control group and 6.00% in the observation group (P < 0.05). One month post-surgery, the observation group showed significantly greater ROM, lower psychological stress and reaction scores, and higher Harris score and quality of life score compared to the control group (all P < 0.05).</p><p><strong>Conclusion: </strong>The MDT nursing model based on ERAS concept for THA/TKA perioperative patients effectively alleviates postoperative pain, promotes early activity, shortens hospital stay, reduces hospital cost, decreases the incidence of complications, restores joint function, enhances quality of life, and reduces psychological stress.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Yipi Huayu decoction on tumor markers, immune function, and adverse reactions during chemotherapy in gastric cancer patients: a retrospective propensity score-matched study. 一品化瘀汤对胃癌患者化疗期间肿瘤标志物、免疫功能和不良反应的影响:一项倾向评分匹配的回顾性研究。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.62347/SRHB1100
Mingchang Zhang, Junning Cuan, Wenjing Wang, Yan Guo, Jianfang Zhao

Objective: To analyze the effects of Yianpi Huayu Decoction on tumor markers, immune function and adverse reactions during chemotherapy in patients with gastric cancer.

Method: The clinical data of 154 patients with progressive gastric cancer who attended Baoji Maternal and Child Health Hospital (Daijiawan Branch) from January 2020 to March 2022 were retrospectively analyzed. The patients were divided into an observation group (61 cases) and a control group (93 cases) according to the treatment method and were matched using propensity score matching (PSM). The control group was given SOX neoadjuvant chemotherapy regimen (oxaliplatin + tiglio), and the observation group was given spleen-strengthening and blood-stasis-reducing tonics as adjuvant treatment on the basis of the treatment given to the control group. Clinical efficacy in the two groups was observed, as well as Carbohydrate Antigen 19-9 (CA19-9), Carbohydrate Antigen 72-4 (CA72-4), and Carcinoembryonic Antigen (CEA) levels, immune function (IgA, IgM, and IgG), Karnofsky Performance Scale (KPS), and occurrence of adverse reactions.

Results: After matching, there was no significant difference in the total clinical efficiency between the two groups (P > 0.05). After matching, there were no differences in CA19-9, CA72-4, and CEA levels between the observation group and the control group before or after treatment (P > 0.05). After matching, the IgA, IgM, and IgG levels in the observation group were significantly better than those in the control group after treatment (P < 0.05). The incidence of leukopenia (P = 0.011) and diarrhea (P = 0.011) during treatment was higher in the control group than in the observation group after matching. The KPS score of the observation group was higher than that of the control group after matching (P < 0.05). After matching, Cox regression analysis found that the treatment regimen (P < 0.001, HR = 2.527), TNM staging (P = 0.001, HR = 0.471), local recurrence (P = 0.001, HR = 2.147), and pretreatment CEA (P = 0.011, HR = 1.131) were independent prognostic factors affecting patients' 2-year survival.

Conclusion: While the spleen-enhancing and blood-stasis-removing herbal formula combined with the SOX chemotherapy regimen did not improve therapeutic outcomes in gastric cancer patients, it did enhance immune function, reduce adverse reactions, and improve quality of life.

目的方法:回顾性分析宝鸡市妇幼保健院(戴家湾分院)2020年1月至2022年3月收治的154例进展期胃癌患者的临床资料:回顾性分析宝鸡市妇幼保健院(戴家湾分院)2020年1月至2022年3月收治的154例进展期胃癌患者的临床资料。根据治疗方法将患者分为观察组(61例)和对照组(93例),并采用倾向评分匹配法(PSM)进行配对。对照组给予 SOX 新辅助化疗方案(奥沙利铂+替格瑞洛),观察组在对照组治疗基础上给予健脾化瘀汤辅助治疗。观察两组的临床疗效,以及碳水化合物抗原19-9(CA19-9)、碳水化合物抗原72-4(CA72-4)和癌胚抗原(CEA)水平、免疫功能(IgA、IgM和IgG)、卡诺夫斯基评分表(KPS)和不良反应发生情况:匹配后,两组临床总有效率无明显差异(P>0.05)。配对后,观察组与对照组治疗前后的CA19-9、CA72-4和CEA水平均无差异(P>0.05)。配对后,观察组的 IgA、IgM 和 IgG 水平明显优于治疗后的对照组(P < 0.05)。治疗期间白细胞减少(P = 0.011)和腹泻(P = 0.011)的发生率,对照组高于配对后的观察组。配对后,观察组的 KPS 评分高于对照组(P < 0.05)。匹配后,Cox回归分析发现,治疗方案(P < 0.001,HR = 2.527)、TNM分期(P = 0.001,HR = 0.471)、局部复发(P = 0.001,HR = 2.147)和治疗前CEA(P = 0.011,HR = 1.131)是影响患者2年生存率的独立预后因素:结论:健脾化瘀中药方剂联合SOX化疗方案虽然不能改善胃癌患者的治疗效果,但能增强患者的免疫功能,减少不良反应,提高生活质量。
{"title":"Effects of Yipi Huayu decoction on tumor markers, immune function, and adverse reactions during chemotherapy in gastric cancer patients: a retrospective propensity score-matched study.","authors":"Mingchang Zhang, Junning Cuan, Wenjing Wang, Yan Guo, Jianfang Zhao","doi":"10.62347/SRHB1100","DOIUrl":"https://doi.org/10.62347/SRHB1100","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the effects of Yianpi Huayu Decoction on tumor markers, immune function and adverse reactions during chemotherapy in patients with gastric cancer.</p><p><strong>Method: </strong>The clinical data of 154 patients with progressive gastric cancer who attended Baoji Maternal and Child Health Hospital (Daijiawan Branch) from January 2020 to March 2022 were retrospectively analyzed. The patients were divided into an observation group (61 cases) and a control group (93 cases) according to the treatment method and were matched using propensity score matching (PSM). The control group was given SOX neoadjuvant chemotherapy regimen (oxaliplatin + tiglio), and the observation group was given spleen-strengthening and blood-stasis-reducing tonics as adjuvant treatment on the basis of the treatment given to the control group. Clinical efficacy in the two groups was observed, as well as Carbohydrate Antigen 19-9 (CA19-9), Carbohydrate Antigen 72-4 (CA72-4), and Carcinoembryonic Antigen (CEA) levels, immune function (IgA, IgM, and IgG), Karnofsky Performance Scale (KPS), and occurrence of adverse reactions.</p><p><strong>Results: </strong>After matching, there was no significant difference in the total clinical efficiency between the two groups (P > 0.05). After matching, there were no differences in CA19-9, CA72-4, and CEA levels between the observation group and the control group before or after treatment (P > 0.05). After matching, the IgA, IgM, and IgG levels in the observation group were significantly better than those in the control group after treatment (P < 0.05). The incidence of leukopenia (P = 0.011) and diarrhea (P = 0.011) during treatment was higher in the control group than in the observation group after matching. The KPS score of the observation group was higher than that of the control group after matching (P < 0.05). After matching, Cox regression analysis found that the treatment regimen (P < 0.001, HR = 2.527), TNM staging (P = 0.001, HR = 0.471), local recurrence (P = 0.001, HR = 2.147), and pretreatment CEA (P = 0.011, HR = 1.131) were independent prognostic factors affecting patients' 2-year survival.</p><p><strong>Conclusion: </strong>While the spleen-enhancing and blood-stasis-removing herbal formula combined with the SOX chemotherapy regimen did not improve therapeutic outcomes in gastric cancer patients, it did enhance immune function, reduce adverse reactions, and improve quality of life.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of factors associated with Helicobacter pylori infection in severe pancreatitis patients and its effect on patient's prognosis. 分析重症胰腺炎患者幽门螺杆菌感染的相关因素及其对患者预后的影响。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.62347/JKEF1700
Wencheng He, Yonggen Zhang

Objective: To analyze the factors related to Helicobacter pylori (Hp) infection in patients with severe acute pancreatitis (SAP) and to observe the effect of Hp on SAP, and to provide a reference for future clinical prevention and treatment of Hp infection in SAP.

Methods: A retrospective analysis was performed on 77 SAP patients admitted to Pingxiang People's Hospital between January 2020 and February 2022, with 33 Hp-infected individuals as the Hp-positive group and the other 44 patients being without Hp infection served as the Hp-negative group. First, the related factors of Hp infection in SAP patients were analyzed with multiple Logistic regression. Subsequently, the Acute Physiology and Chronic Health Evaluation II (APACHE II), Bedside Index for Severity in Acute Pancreatitis (BISAP) and Modified CT Severity Index (MCTSI) scores, as well as the levels of C-reactive protein (CRP), white blood cell (WBC), procalcitonin (PCT) and immunoglobulins A/M/G (IgA, IgM, and IgG) were recorded for inter-group comparisons. The adverse reactions and hospitalization time were also recorded. Besides, a six-month follow-up was carried out after discharge, and patients' quality of life was evaluated using the Short-Form 36 Item Health Survey (SF-36).

Results: Logistic regression analysis identified that history of Hp infection, long-term drinking, eating habits and history of biliary tract diseases were independent risk factors for Hp infection (all P<0.05). At 2 weeks after admission, higher APACHE II, BISAP and MCTSI scores were observed in Hp-positive group compared with Hp-negative group (all P<0.05). The Hp-positive group exhibited higher CRP, WBC and PCT levels while lower IgA, IgM and IgG levels during treatment compared to the Hp-negative group (all P<0.05). No difference was found in the incidence of adverse reactions between the two groups (P>0.05), but the hospitalization time of the Hp-positive group was significantly prolonged (P<0.05). The follow-up results determined better quality of life in the Hp-negative group, which resulted in higher SF-36 scores in various dimensions (P<0.05).

Conclusion: The history of Hp infection, long-term drinking, eating habits, and history of biliary tract diseases are all independent risk factors for Hp infection. Hp infection exacerbates disease progression of SAP, adversely influences patients' recovery, impairs their immune function, and compromises their prognoses.

目的分析重症急性胰腺炎(SAP)患者幽门螺杆菌(Hp)感染的相关因素,观察Hp对SAP的影响,为今后临床防治SAP感染Hp提供参考:方法:对萍乡市人民医院2020年1月至2022年2月期间收治的77例SAP患者进行回顾性分析,其中33例Hp感染者为Hp阳性组,其余44例无Hp感染者为Hp阴性组。首先,采用多元 Logistic 回归分析 SAP 患者感染 Hp 的相关因素。随后,记录急性生理学和慢性健康评估 II(APACHE II)、急性胰腺炎床旁严重程度指数(BISAP)和改良 CT 严重程度指数(MCTSI)的评分,以及 C 反应蛋白(CRP)、白细胞(WBC)、降钙素原(PCT)和免疫球蛋白 A/M/G (IgA、IgM 和 IgG)的水平,以进行组间比较。还记录了不良反应和住院时间。此外,出院后还进行了为期六个月的随访,并使用短表 36 项健康调查(SF-36)对患者的生活质量进行了评估:Logistic回归分析发现,Hp感染史、长期饮酒、饮食习惯和胆道疾病史是Hp感染的独立危险因素(均为P0.05),但Hp阳性组的住院时间明显延长(PConclusion:Hp感染史、长期饮酒、饮食习惯和胆道疾病史都是Hp感染的独立危险因素。Hp 感染会加剧 SAP 的病情发展,对患者的康复产生不利影响,损害患者的免疫功能,影响患者的预后。
{"title":"Analysis of factors associated with Helicobacter pylori infection in severe pancreatitis patients and its effect on patient's prognosis.","authors":"Wencheng He, Yonggen Zhang","doi":"10.62347/JKEF1700","DOIUrl":"https://doi.org/10.62347/JKEF1700","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the factors related to Helicobacter pylori (Hp) infection in patients with severe acute pancreatitis (SAP) and to observe the effect of Hp on SAP, and to provide a reference for future clinical prevention and treatment of Hp infection in SAP.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 77 SAP patients admitted to Pingxiang People's Hospital between January 2020 and February 2022, with 33 Hp-infected individuals as the Hp-positive group and the other 44 patients being without Hp infection served as the Hp-negative group. First, the related factors of Hp infection in SAP patients were analyzed with multiple Logistic regression. Subsequently, the Acute Physiology and Chronic Health Evaluation II (APACHE II), Bedside Index for Severity in Acute Pancreatitis (BISAP) and Modified CT Severity Index (MCTSI) scores, as well as the levels of C-reactive protein (CRP), white blood cell (WBC), procalcitonin (PCT) and immunoglobulins A/M/G (IgA, IgM, and IgG) were recorded for inter-group comparisons. The adverse reactions and hospitalization time were also recorded. Besides, a six-month follow-up was carried out after discharge, and patients' quality of life was evaluated using the Short-Form 36 Item Health Survey (SF-36).</p><p><strong>Results: </strong>Logistic regression analysis identified that history of Hp infection, long-term drinking, eating habits and history of biliary tract diseases were independent risk factors for Hp infection (all P<0.05). At 2 weeks after admission, higher APACHE II, BISAP and MCTSI scores were observed in Hp-positive group compared with Hp-negative group (all P<0.05). The Hp-positive group exhibited higher CRP, WBC and PCT levels while lower IgA, IgM and IgG levels during treatment compared to the Hp-negative group (all P<0.05). No difference was found in the incidence of adverse reactions between the two groups (P>0.05), but the hospitalization time of the Hp-positive group was significantly prolonged (P<0.05). The follow-up results determined better quality of life in the Hp-negative group, which resulted in higher SF-36 scores in various dimensions (P<0.05).</p><p><strong>Conclusion: </strong>The history of Hp infection, long-term drinking, eating habits, and history of biliary tract diseases are all independent risk factors for Hp infection. Hp infection exacerbates disease progression of SAP, adversely influences patients' recovery, impairs their immune function, and compromises their prognoses.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of translational research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1